Why Is Cellectar Biosciences (CLRB) Stock Up 16% Today?
Share- Nishadil
- January 08, 2024
- 0 Comments
- 1 minutes read
- 61 Views
Cellectar Biosciences (NASDAQ: CLRB ) stock is heading higher on Monday after the company posted positive results from its CLOVER WaM study of iopofosine I 131. According to a press release from the company, iopofosine I 131 performed well in the trial as a potential first in class, targeted radiotherapy candidate to treat patients with relapsed/refractory Waldenstrom’s macroglobulinemia that have already undergone a minimum of two previous forms of therapy.
Cellectar Biosciences notes that the study met its primary endpoint with a 61% major response rate. The company also saw an overall response rate of 75.6% in evaluable patients and 100% of patients recorded disease control. Sikander Ailawadhi, M.D., professor of medicine at Mayo Clinic, and lead investigator in the CLOVER WaM study, said the following.
How This Affects CLRB Stock Today With this news comes heavy trading of CLRB shares on Monday. That has more than 5.7 million shares of the company’s stock changing hands as of this writing. This is well above its daily average trading volume of only about 319,000 shares. CLRB stock is up 16.2% as of Monday morning.
Investors looking for more of the most recent stock market stories are in the right place! InvestorPlace is home to all of the hottest stock market news worth reading about on Monday! Among that is why shares of Harpoon Therapeutics (NASDAQ: HARP ) stock are up, the biggest pre market stock movers this morning and more.
All of that info is ready to go at the following links! More Stock Market News for Monday Why Is Harpoon Therapeutics (HARP) Stock Up 111% Today? Today’s Biggest Pre Market Stock Movers: 10 Top Gainers and Losers on Monday Lawmakers Want EV Makers to Stay Out of Union Negotiations. That Would Be Good for EV Stocks, Too.
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines ..
